Peter Wirth
CIK 1021041 · Exec VP,Legal & Corporate Dev. · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GENZ price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
BOSTON, MA 02114
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZLAB | Director | 420,121 | $24.34 | $10.23M | $293.3K | 9 | 2026-06-22 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | Director | 16,000 | $0.00 | $6 | $0 | 9 | 2024-06-07 |
| Forma Therapeutics Holdings, Inc. (FMTX) Delisted | Director | 0 | $20.01 | $0 | $0 | 5 | 2022-10-14 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | — | — | — | $0 | 3 | 2015-06-23 |
| GENZ | Exec VP,Legal & Corporate Dev. | 0 | $37.37 | $0 | -$18.18M | 8 | 2011-04-06 |
Recent Filings · Page 3 of 4
35 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-11 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-12 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-15 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-01-30 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-23 | SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Disp (D) | — | $0 | EDGAR |
| 2013-06-10 | SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-06-29 | SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-04-06 | GENZ | Mixed | −15,808 | -$3.33M | EDGAR |
| 2010-06-18 | GENZ | Grant (A) | — | $0 | EDGAR |
| 2010-05-26 | GENZ | Mixed | +8,335 | -$304.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.